Related Experiment Video
Updated: Jul 5, 2026

A Novel Clinical Grade Isolation Method for Human Kidney Perivascular Stromal Cells
Published on: August 7, 2017
Plasma exchange for myeloma kidney: cast(s) away?
1Division of Nephrology, University of Western Ontario, London, Ontario, Canada. william.clark@lhsc.on.ca
Plasma exchange may not improve outcomes for myeloma kidney disease. Further randomized controlled trials are needed to confirm findings and guide treatment decisions, rather than off-label use.
Area of Science:
- Nephrology
- Hematology
- Clinical Trials
Background:
- Myeloma kidney, a complication of multiple myeloma, affects kidney function.
- Plasma exchange has been considered as a treatment for light-chain responsive myeloma kidney.
Discussion:
- Leung et al. studied 40 patients, suggesting plasma exchange for myeloma kidney.
- Analysis of their data and a recent RCT shows minimal outcome differences between plasma exchange and control groups.
Key Insights:
- Current evidence does not strongly support plasma exchange for myeloma kidney.
- More robust randomized controlled trials are necessary to establish efficacy.
Outlook:
- Future research should focus on designing better RCTs for plasma exchange in myeloma kidney.
- Avoidance of off-label plasma exchange use is recommended pending further evidence.
Related Concept Videos
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Kidney Transplant II: Surgical Procedure
Acute Kidney Injury V: Interprofessional Care
Kidney Transplant III: Nursing Management
